Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | M1774 + M4076 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
M1774 | M-1774|M 1774|tuvusertib | ATR Inhibitor 16 | M1774 inhibits ATR, potentially resulting in decreased tumor growth (PMID: 38407317). | |
M4076 | M 4076|M-4076|Lartesertib | ATM Inhibitor 13 | M4076 inhibits ATM, potentially resulting in reduced tumor growth (PMID: 35405736). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06433219 | Phase II | M1774 + Niraparib M1774 + M4076 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | Recruiting | USA | 0 |